Roman Hauk @Haukro: "Keeping all four positions unchanged..."

Slovakia

Keeping all four positions unchanged this week - TX 2.18%, EPD 2.17%, CSG 1.43%, VRDN 0.91%. Together that's 6.69% of the portfolio, sized for very different risk levels. $CSG.NV (Czechoslovak Group) bought the 57-hectare Gnaschwitz site in Saxony and plans over €100 million for nitroglycerin, ammunition and components. Good move for vertical integration, but permits and future capacity use will decide if it pays off. No dividend before 2027, this stays for now a pure growth and supply-chain bet in defense. $VRDN (Viridian Therapeutics Inc) just went commercial after Lumvoa's FDA approval and US launch, already reaching 95% of its 2,000 core prescribers by July 31. Q2 still showed a $127.1 million net loss, so I'm holding this one under 1% despite the $36.75 analyst target. Also no dividend, this is early-stage biotech risk, not income. $EPD (Enterprise Products Partners LP) the income anchor - $2.3 billion Q2 DCF, 1.9x coverage, close to 5.9% forward yield. 2026 revenue forecast increased from US$54.9b to US$62.6b. EPS estimate increased from US$2.87 to US$2.98 per share. Net income forecast to grow 7.6% next year vs 29% growth forecast for Oil and Gas industry in the US. $TX (Ternium SA-ADR) posted $4.34 billion revenue and $1.75 EPS, forward yield around 4.6%. Second quarter 2026 results. EPS US$1.75 (up from US$1.10 in 2Q 2025). Revenue US$4.34b (up 10.0% from 2Q 2025). Net income US$343.7m (up 60% from 2Q 2025). Profit margin 7.9% (up from 5.5% in 2Q 2025). One good quarter doesn't change my sizing on either. Still fine-tuning my prep for the next DCA buy around August 14-17... ✌️😎

Not investment advice. The author may have financial interests in the mentioned instruments.

4 Mentioned

CSG.NV

Czechoslovak Group

VRDN

Viridian Therapeutics Inc

EPD

Enterprise Products Partners LP

Ternium SA-ADR

Strictly Necessary Cookies

Performance Cookies

Functional Cookies

Targeting Cookies